Lista de obras -

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study

artículo científico publicado en 2008

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

artículo científico publicado en 2011

Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.

artículo científico publicado en 2017

Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

artículo científico publicado en 2017

IAP antagonists induce anti-tumor immunity in multiple myeloma.

artículo científico publicado en 2016

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs

scientific article published on 23 July 2015

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers ⬇️

artículo científico publicado el 10 de enero de 2011

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.

artículo científico

Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.

artículo científico publicado en 2012

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1

artículo científico publicado en 2016

Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed, Lenalidomide Refractory Multiple Myeloma

artículo científico publicado en 2017

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.

artículo científico publicado en 2017

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

artículo científico publicado en 2010

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

artículo científico publicado en 2009

Smoldering multiple myeloma requiring treatment: time for a new definition?

artículo científico publicado en 2013

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study

artículo científico publicado en 2011

Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy

artículo científico publicado en 2017

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.

artículo científico publicado en 2019

Lista de obras de

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.

Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

IAP antagonists induce anti-tumor immunity in multiple myeloma.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers ⬇️

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.

Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1

Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed, Lenalidomide Refractory Multiple Myeloma

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

Smoldering multiple myeloma requiring treatment: time for a new definition?

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study

Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.